EMZ702 + pegylated interferon + ribavirin

EMZ702 + pegylated interferon + ribavirin is an investigational combination drug regimen for the treatment of chronic hepatitis C. **EMZ702** is a non-toxic agent, chemically synthesized, that shows strong anti-viral synergy when combined with interferon-based therapies. In preclinical models, **EMZ702** combined with pegylated interferon and ribavirin produced a two to threefold increase in anti-viral potency versus standard pegylated interferon plus ribavirin. **Pegylated interferon** is an engineered form of interferon alpha with increased bioavailability and extended half-life, making it suitable for weekly subcutaneous injections. **Ribavirin** is a nucleoside analog antiviral. The combination targets viral replication and modulates the host immune response, with substantial evidence from clinical trials and surrogate models supporting efficacy especially in hepatitis C virus (HCV) infections[1][2][8]. The regimen is under development and does not have a unique brand name or commercial manufacturer associated with the combination; EMZ702 is sometimes referenced as thymalfasin (thymosin alpha 1), which is approved in some countries[1].